Skip To Main Content
Barbara Jarzab on Muck Rack

Barbara Jarzab

As seen in: Wiley Online Library, Frontiers, touchENDOCRINOLOGY, Salud Ediciones
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study

|
By Barbara Jarzab, Jolanta Krajewska, Shunji Takahashi
| Frontiers
1 Introduction Thyroid cancer accounts for 1% of all cancer cases and 90% of malignant endocrine tumors. The prognosis of thyroid cancer is favorable, with a 10-year survival rate of 85%. Further, the incidence of distant metastasis is less than 5%, and 10-year survival in patients with metastasis is 25%–42% (1, 2).
Open in Who Shared Issue with article?

Family history of malignant or benign thyroid tumors: implications for surgical procedure management and disease-free survival

|
By Artur Bossowski, Barbara Jarzab, Lilah F. Morris-Wiseman
| Frontiers
1 Introduction Currently, the most contentious issue regarding family history of thyroid carcinoma is familial non-medullary thyroid carcinoma (FNMTC), which accounts for approximately 5-10% of all cases of thyroid carcinoma (1). FNMTC is characterized by the presence of two or more first-degree relatives affected by non-medullary thyroid carcinoma.
Open in Who Shared Issue with article?

The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib

|
By Jadwiga Furmaniak, Barbara Jarzab, Yuanna Ling, Longfei Deng
| Frontiers
1Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China 2Department of Ultrasound Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China Background: Sorafenib included in Chinese medical insurance is the earliest targeted drug for radioactive iodine refractory differentiated thyroid cancer (RR-DTC).
Open in Who Shared Issue with article?
See all 11 articles